Posted by Michael Wonder on 29 Nov 2017
Is the FDA withholding data about a controversial drug to protect its manufacturer?
29 November 2017 - In the case of Sarepta, it sure looks that way.
The FDA is seldom accused of being too transparent. But in late September, it looked like the agency had overshared.
In an attempt to achieve the "greatest level of transparency," the agency caused the stock prices of four biotech companies to hemorrhage. Jittery traders, sifting through scraps of context-free information provided by the agency, dumped their drug stocks, triggering a brief but brutal plunge.
